{'fraction_non_alphanumeric': 0.024602026049204053, 'fraction_numerical': 0.0, 'mean_word_length': 5.290909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Macrophage inhibitor factor (MIF) in cutaneous lymphoproliferative diseases

Macrophage migration inhibitor factor (MIF) activity in the sera of patients with mycosis fungoides, Sezary syndrome, and cutaneous lymphoma was observed in the sera of eight of the ten patients with stage II (infiltrative) mycosis fungoides, but in only one of the eight patients with stage I and in neither of the two patients with stage III mycosis fungoides. Two of the three patients with Sezary syndrome had MIF in the serum. No MIF was observed in cutaneous lymphoma. These data support the concept that Sezary syndrome and mycosis fungoides are T‐cell diseases, and transitional, pre‐lymphomatous diseases.